Your Location：Home >Products >Custom peptide >108736-35-2

108736-35-2

  • Product NameLanreotide
  • Molecular FormulaC54H69N11O10S2
  • Molecular Weight1096.34
  • Purity99%
Inquiry

Product Details

Quick Details

  • CasNo： 108736-35-2
  • Molecular Formula： C54H69N11O10S2
  • Purity： 99%

Buy High Quality Lanreotide, Offer 108736-35-2 Cheapest Price

  • Molecular Formula:C54H69N11O10S2
  • Molecular Weight:1096.34
  • Boiling Point:1498.3 °C at 760 mmHg 
  • PKA:9.90±0.15(Predicted) 
  • Flash Point:859.9 °C 
  • PSA：405.68000 
  • Density:1.323 g/cm3 
  • LogP:5.34830 

Lanreotide(Cas 108736-35-2) Usage

Chemical Properties

White to off-white lyophilised powder

Uses

Antineoplas tic.

Clinical Use

#N/A

InChI:InChI=1/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)

108736-35-2 Relevant articles

Solid phase peptide synthesis via side chain attachment

-

Page/Page column 6; 26, (2016/08/10)

The present application discloses peptid...

Boc and Fmoc solid phase peptide synthesis

-

Page/Page column 10, (2013/03/26)

A solid phase method for synthesizing a ...

USE OF SUBSTITUTED 2 PHENYLBENZIMIDAZOLES AS MEDICAMENTS

-

, (2008/06/13)

The present invention relates to the use...

Pharmaceutical compositions containing growth-hormone inhibitors or their biologically active fragments for the treatment of uterine myomas

-

, (2008/06/13)

Pharmaceutical compositions containing g...

108736-35-2 Process route

H-D-β-Nal-Cys-(Acm)-Tyr-D-Trp-Lys-Val-Cys(Acm)-Thr-NH<sub>2</sub>
1026080-86-3

H-D-β-Nal-Cys-(Acm)-Tyr-D-Trp-Lys-Val-Cys(Acm)-Thr-NH2

lanreotide
108736-35-2

lanreotide

Conditions
Conditions Yield
With iodine; acetic acid; In methanol; at 55 ℃; for 0.25h; Inert atmosphere;
350 mg
Fmoc-Tyr(Clt)-OH
350241-80-4

Fmoc-Tyr(Clt)-OH

Fmoc-Val-OH
68858-20-8

Fmoc-Val-OH

Boc-Lys(Boc)-OH
2483-46-7

Boc-Lys(Boc)-OH

Fmoc-Thr-NH<sub>2</sub>

Fmoc-Thr-NH2

Boc-D-2Nal-OH
76985-10-9

Boc-D-2Nal-OH

Fmoc-Trp-OH
35737-15-6

Fmoc-Trp-OH

N-(9-fluorenylmethoxycarbonyl)-S-trityl-L-cysteine
103213-32-7,167015-11-4

N-(9-fluorenylmethoxycarbonyl)-S-trityl-L-cysteine

lanreotide
108736-35-2

lanreotide

Conditions
Conditions Yield
Fmoc-Thr-NH2; With benzotriazol-1-ol; diisopropyl-carbodiimide; In 1-methyl-pyrrolidin-2-one; dichloromethane; at 0 - 30 ℃;
With piperidine; In 1-methyl-pyrrolidin-2-one;
Fmoc-Tyr(Clt)-OH; Fmoc-Val-OH; Boc-Lys(Boc)-OH; Boc-D-2Nal-OH; Fmoc-Trp-OH; N-(9-fluorenylmethoxycarbonyl)-S-trityl-L-cysteine; Further stages;
 

108736-35-2 Upstream products

  • 1026080-86-3
    1026080-86-3

    H-D-β-Nal-Cys-(Acm)-Tyr-D-Trp-Lys-Val-Cys(Acm)-Thr-NH2

  • 350241-80-4
    350241-80-4

    Fmoc-Tyr(Clt)-OH

  • 68858-20-8
    68858-20-8

    Fmoc-Val-OH

  • 2483-46-7
    2483-46-7

    Boc-Lys(Boc)-OH

Relevant Products

Links:
Copyright © 2024 Sichuan Jisheng Biopharmaceutical Co.,Ltd ICP NO.:Zhejiang000000